Managing the COVID-19 Drug Safety Response

Managing the COVID-19 Drug Safety Response


Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

What you will learn:

  • Limitations of current safety reporting systems for COVID-19 treatment and vaccination initiatives
  • Requirements for COVID-19 safety data capture to ensure signals are detected and assessed at the earliest opportunity
  • Risk reduction in particular during the rapid exposure likely during mass vaccination campaigns

Fill out the form below to download the whitepaper:

By submitting your information you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing


We use analytical cookies that need your permission. For more details and advanced options view our Cookies Policy.